22 Oct 2026, 08:39 IST
Emcure Pharmaceuticals Limited
Motilal Oswal Financial Services Ltd. (MOFSL) · BUY · target INR 2,330
The report highlights Emcure's domestic formulations growth of 19.3% YoY outperforming the IPM and assigns a BUY rating with 33% upside to target.
From MOStMarketOutlook22102026, written by Motilal Oswal Financial Services Ltd. (MOFSL) and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd. (MOFSL)'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.